Literature DB >> 15912468

Qualitative venous Doppler flow waveform analysis in preterm intrauterine growth-restricted fetuses with ARED flow in the umbilical artery--correlation with short-term outcome.

A Schwarze1, U Gembruch, M Krapp, A Katalinic, U Germer, R Axt-Fliedner.   

Abstract

OBJECTIVE: The aim of this retrospective study was to examine the significance of severe Doppler waveform abnormalities in the ductus venosus (DV) and the umbilical vein (UV) for the prediction of adverse outcomes in very preterm growth-restricted fetuses with absent or reversed end-diastolic flow in the umbilical artery (UA) at 24-34 weeks of gestation.
METHODS: Seventy-four fetuses with intrauterine growth restriction (IUGR) and absent or reversed end-diastolic (ARED) flow in the UA at 24-34 weeks of gestation, which were delivered before 34 weeks' gestation, were examined. Absent or reversed flow during atrial contraction (a-wave) in the DV and pulsatile flow in the UV were examined to predict severe perinatal outcomes (stillbirth, neonatal death, perinatal death, acidemia, 5 min Apgar < 7, intraventricular hemorrhage and elevated nucleated red blood cell counts at delivery).
RESULTS: Twelve (16.2%) perinatal deaths, of which eight were stillbirths (10.8%), and two (2.7%) neonatal deaths occurred among 74 fetuses. Logistic regression analysis confirmed that abnormal DV Doppler waveforms (R2 = 0.57, P < 0.001) together with gestational age at delivery (R2 = 0.57, P < 0.001) showed the strongest association with perinatal death, whereas only gestational age was significantly related to neonatal death (R2 = 0.67, P < 0.05). Abnormal DV Doppler waveforms (R2 = 0.86, P < 0.001) and gestational age (R2 = 0.49, P < 0.05) were strongly associated with adverse outcome (including stillbirth, perinatal death or neonatal death). Abnormal venous Doppler flow patterns performed better in the prediction of fetal or perinatal demise than did ARED flow or brain sparing.
CONCLUSION: Abnormal venous Doppler waveforms in preterm IUGR fetuses with ARED flow are strongly related to adverse fetal and perinatal outcomes before 32 weeks of gestation. The possible benefit of prolonging these pregnancies can only be evaluated in a prospective randomized study. Copyright 2005 ISUOG

Entities:  

Mesh:

Year:  2005        PMID: 15912468     DOI: 10.1002/uog.1914

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  4 in total

Review 1.  Clinical Opinion: The diagnosis and management of suspected fetal growth restriction: an evidence-based approach.

Authors:  Christoph C Lees; Roberto Romero; Tamara Stampalija; Andrea Dall'Asta; Greggory A DeVore; Federico Prefumo; Tiziana Frusca; Gerard H A Visser; John C Hobbins; Ahmet A Baschat; Caterina M Bilardo; Henry L Galan; Stuart Campbell; Dev Maulik; Francesc Figueras; Wesley Lee; Julia Unterscheider; Herbert Valensise; Fabricio Da Silva Costa; Laurent J Salomon; Liona C Poon; Enrico Ferrazzi; Giancarlo Mari; Giuseppe Rizzo; John C Kingdom; Torvid Kiserud; Kurt Hecher
Journal:  Am J Obstet Gynecol       Date:  2022-01-10       Impact factor: 10.693

Review 2.  Early onset fetal growth restriction.

Authors:  Andrea Dall'Asta; Valentina Brunelli; Federico Prefumo; Tiziana Frusca; Christoph C Lees
Journal:  Matern Health Neonatol Perinatol       Date:  2017-01-18

3.  Dexamethasone on absent end-diastolic flow in umbilical artery, in growth restricted fetuses from early-onset preeclamptic pregnancies and the perinatal outcome.

Authors:  Oana Sorina Tica; Andrei Adrian Tica; Doriana Cojocaru; Mihaela Gheonea; Irina Tica; Dragos Ovidiu Alexandru; Victor Cojocaru; Lucian Cristian Petcu; Vlad Iustin Tica
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

4.  Infant outcome after active management of early-onset fetal growth restriction with absent or reversed umbilical artery blood flow.

Authors:  E Morsing; J Brodszki; A Thuring; K Maršál
Journal:  Ultrasound Obstet Gynecol       Date:  2021-06       Impact factor: 7.299

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.